---
document_datetime: 2025-12-02 05:09:17
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/xydalba.html
document_name: xydalba.html
version: success
processing_time: 0.1155307
conversion_datetime: 2025-12-26 11:15:13.817199
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Xydalba

[RSS](/en/individual-human-medicine.xml/65787)

##### Authorised

This medicine is authorised for use in the European Union

dalbavancin Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Xydalba](#news-on)
- [More information on Xydalba](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Xydalba is an antibiotic used in adults and children of all ages to treat acute (short-term) bacterial infections of the skin and of skin structures (tissue below the skin) such as cellulitis (inflammation of the deep skin tissue), skin abscesses and wound infections. It contains the active substance dalbavancin.

Expand section

Collapse section

## How is Xydalba used?

Xydalba is given by infusion (drip) into a vein over 30 minutes. For adults it is given either as a single infusion or as two infusions one week apart. For children, it is given as a single infusion, and the dose depends on age and body weight.

Xydalba can only be obtained with a prescription and prescribers should take into account official guidance on the use of antibiotics.

For more information about using Xydalba, see the package leaflet or contact your doctor or pharmacist.

## How does Xydalba work?

The active substance in Xydalba, dalbavancin, is a type of antibiotic called a glycopeptide. It works by preventing certain bacteria from making their own cell walls, thereby killing the bacteria. Dalbavancin has been shown to work against bacteria (such as methicillin-resistant *Staphylococcus aureus* (MRSA)) for which standard antibiotics do not work. A list of bacteria against which Xydalba is active can be found in the summary of product characteristics.

## What benefits of Xydalba have been shown in studies?

Xydalba was compared with vancomycin (another glycopeptide) or with linezolid (another type of antibiotic, which can be taken by mouth) in three main studies involving a total of around 2,000 adults with serious infections of the skin and soft tissue under the skin, such as cellulitis, skin abscesses and wound infections. These also included infections caused by MRSA.

Patients who received vancomycin and responded to treatment had the option to switch to linezolid after 3 days. In all the studies, the main measure of effectiveness was the number of patients whose infection was cured after treatment.

Xydalba was at least as effective as vancomycin or linezolid at curing the infection. In the 3 studies, between 87% and 94% of patients treated with Xydalba were cured, compared with between 91% and 93% of patients treated with any of the two comparators.

A study involving 199 children (including newborn babies) with serious infections of the skin and soft tissue under the skin found that Xydalba, given as a single dose or as two doses one week apart, resulted in levels of the active substance in the body similar to those seen in adults. Therefore, Xydalba is expected to have a comparable effect in children as in adults.

## What are the risks associated with Xydalba?

For the full list of side effects and restrictions with Xydalba, see the package leaflet.

The most common side effects with Xydalba (which may affect more than 1 in 100 people) include nausea (feeling sick), diarrhoea and headache. These side effects were generally of mild or moderate severity.

## Why is Xydalba authorised in the EU?

The European Medicines Agency decided that Xydalba's benefits are greater than its risks and it can be authorised for use in the EU. In light of the need for new antibiotics targeting multi-resistant bacteria, the Agency concluded that Xydalba, which showed activity in adults against certain bacteria resistant to other antibiotics, could be a valuable alternative treatment option. The Agency also considered that the effect and safety profile of Xydalba in children are expected to be comparable to those seen in adults.

Xydalba's safety profile is comparable to that of other glycopeptide antibiotics; side effects affecting hearing and kidney function, which are typical for glycopeptides, have not been shown with the proposed regimens of Xydalba in the clinical trials.

## What measures are being taken to ensure the safe and effective use of Xydalba?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Xydalba have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Xydalba are continuously monitored. Suspected side effects reported with Xydalba are carefully evaluated and any necessary action taken to protect patients.

## Other information about Xydalba

Xydalba received a marketing authorisation valid throughout the EU on 19 February 2015.

Xydalba : EPAR - Medicine overview

Reference Number: EMA/172603/2025

English (EN) (120.95 KB - PDF)

**First published:** 05/03/2015

**Last updated:** 01/07/2025

[View](/en/documents/overview/xydalba-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-99)

български (BG) (145.21 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

01/07/2025

[View](/bg/documents/overview/xydalba-epar-medicine-overview_bg.pdf)

español (ES) (111.97 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

01/07/2025

[View](/es/documents/overview/xydalba-epar-medicine-overview_es.pdf)

čeština (CS) (144.23 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

01/07/2025

[View](/cs/documents/overview/xydalba-epar-medicine-overview_cs.pdf)

dansk (DA) (120.84 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

01/07/2025

[View](/da/documents/overview/xydalba-epar-medicine-overview_da.pdf)

Deutsch (DE) (125.35 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

01/07/2025

[View](/de/documents/overview/xydalba-epar-medicine-overview_de.pdf)

eesti keel (ET) (119.14 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

01/07/2025

[View](/et/documents/overview/xydalba-epar-medicine-overview_et.pdf)

ελληνικά (EL) (144.88 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

01/07/2025

[View](/el/documents/overview/xydalba-epar-medicine-overview_el.pdf)

français (FR) (123.69 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

01/07/2025

[View](/fr/documents/overview/xydalba-epar-medicine-overview_fr.pdf)

hrvatski (HR) (143.74 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

01/07/2025

[View](/hr/documents/overview/xydalba-epar-medicine-overview_hr.pdf)

italiano (IT) (111.45 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

01/07/2025

[View](/it/documents/overview/xydalba-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (151.32 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

01/07/2025

[View](/lv/documents/overview/xydalba-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (144.31 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

01/07/2025

[View](/lt/documents/overview/xydalba-epar-medicine-overview_lt.pdf)

magyar (HU) (144.33 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

01/07/2025

[View](/hu/documents/overview/xydalba-epar-medicine-overview_hu.pdf)

Malti (MT) (144.84 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

01/07/2025

[View](/mt/documents/overview/xydalba-epar-medicine-overview_mt.pdf)

Nederlands (NL) (120.58 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

01/07/2025

[View](/nl/documents/overview/xydalba-epar-medicine-overview_nl.pdf)

polski (PL) (146.39 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

01/07/2025

[View](/pl/documents/overview/xydalba-epar-medicine-overview_pl.pdf)

português (PT) (123.15 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

01/07/2025

[View](/pt/documents/overview/xydalba-epar-medicine-overview_pt.pdf)

română (RO) (149.54 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

01/07/2025

[View](/ro/documents/overview/xydalba-epar-medicine-overview_ro.pdf)

slovenčina (SK) (143.88 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

01/07/2025

[View](/sk/documents/overview/xydalba-epar-medicine-overview_sk.pdf)

slovenščina (SL) (142.39 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

01/07/2025

[View](/sl/documents/overview/xydalba-epar-medicine-overview_sl.pdf)

Suomi (FI) (119.33 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

01/07/2025

[View](/fi/documents/overview/xydalba-epar-medicine-overview_fi.pdf)

svenska (SV) (120.17 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

01/07/2025

[View](/sv/documents/overview/xydalba-epar-medicine-overview_sv.pdf)

Xydalba : EPAR - Risk-management-plan

English (EN) (1.68 MB - PDF)

**First published:** 27/06/2024

**Last updated:** 06/05/2025

[View](/en/documents/rmp/xydalba-epar-risk-management-plan_en.pdf)

## Product information

Xydalba : EPAR - Product Information

English (EN) (338.37 KB - PDF)

**First published:** 05/03/2015

**Last updated:** 20/11/2025

[View](/en/documents/product-information/xydalba-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-647)

български (BG) (372.64 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

20/11/2025

[View](/bg/documents/product-information/xydalba-epar-product-information_bg.pdf)

español (ES) (314.45 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

20/11/2025

[View](/es/documents/product-information/xydalba-epar-product-information_es.pdf)

čeština (CS) (369.53 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

20/11/2025

[View](/cs/documents/product-information/xydalba-epar-product-information_cs.pdf)

dansk (DA) (308.23 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

20/11/2025

[View](/da/documents/product-information/xydalba-epar-product-information_da.pdf)

Deutsch (DE) (313.05 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

20/11/2025

[View](/de/documents/product-information/xydalba-epar-product-information_de.pdf)

eesti keel (ET) (296.25 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

20/11/2025

[View](/et/documents/product-information/xydalba-epar-product-information_et.pdf)

ελληνικά (EL) (400.59 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

20/11/2025

[View](/el/documents/product-information/xydalba-epar-product-information_el.pdf)

français (FR) (336.2 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

20/11/2025

[View](/fr/documents/product-information/xydalba-epar-product-information_fr.pdf)

hrvatski (HR) (355.53 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

20/11/2025

[View](/hr/documents/product-information/xydalba-epar-product-information_hr.pdf)

íslenska (IS) (295.85 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

20/11/2025

[View](/is/documents/product-information/xydalba-epar-product-information_is.pdf)

italiano (IT) (299.88 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

20/11/2025

[View](/it/documents/product-information/xydalba-epar-product-information_it.pdf)

latviešu valoda (LV) (357.02 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

20/11/2025

[View](/lv/documents/product-information/xydalba-epar-product-information_lv.pdf)

lietuvių kalba (LT) (352.46 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

20/11/2025

[View](/lt/documents/product-information/xydalba-epar-product-information_lt.pdf)

magyar (HU) (368.67 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

20/11/2025

[View](/hu/documents/product-information/xydalba-epar-product-information_hu.pdf)

Malti (MT) (429.27 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

20/11/2025

[View](/mt/documents/product-information/xydalba-epar-product-information_mt.pdf)

Nederlands (NL) (312.05 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

20/11/2025

[View](/nl/documents/product-information/xydalba-epar-product-information_nl.pdf)

norsk (NO) (342.71 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

20/11/2025

[View](/no/documents/product-information/xydalba-epar-product-information_no.pdf)

polski (PL) (370.08 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

20/11/2025

[View](/pl/documents/product-information/xydalba-epar-product-information_pl.pdf)

português (PT) (382.16 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

20/11/2025

[View](/pt/documents/product-information/xydalba-epar-product-information_pt.pdf)

română (RO) (369.37 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

20/11/2025

[View](/ro/documents/product-information/xydalba-epar-product-information_ro.pdf)

slovenčina (SK) (370.34 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

20/11/2025

[View](/sk/documents/product-information/xydalba-epar-product-information_sk.pdf)

slovenščina (SL) (347.74 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

20/11/2025

[View](/sl/documents/product-information/xydalba-epar-product-information_sl.pdf)

Suomi (FI) (297.67 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

20/11/2025

[View](/fi/documents/product-information/xydalba-epar-product-information_fi.pdf)

svenska (SV) (293.87 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

20/11/2025

[View](/sv/documents/product-information/xydalba-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000313336 20/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Xydalba : EPAR - All Authorised presentations

English (EN) (20.9 KB - PDF)

**First published:** 05/03/2015

**Last updated:** 05/03/2015

[View](/en/documents/all-authorised-presentations/xydalba-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-835)

български (BG) (35.99 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

05/03/2015

[View](/bg/documents/all-authorised-presentations/xydalba-epar-all-authorised-presentations_bg.pdf)

español (ES) (16.52 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

05/03/2015

[View](/es/documents/all-authorised-presentations/xydalba-epar-all-authorised-presentations_es.pdf)

čeština (CS) (30.73 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

05/03/2015

[View](/cs/documents/all-authorised-presentations/xydalba-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (16.41 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

05/03/2015

[View](/da/documents/all-authorised-presentations/xydalba-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (16.43 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

05/03/2015

[View](/de/documents/all-authorised-presentations/xydalba-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (16.48 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

05/03/2015

[View](/et/documents/all-authorised-presentations/xydalba-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (35.38 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

05/03/2015

[View](/el/documents/all-authorised-presentations/xydalba-epar-all-authorised-presentations_el.pdf)

français (FR) (16.43 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

05/03/2015

[View](/fr/documents/all-authorised-presentations/xydalba-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (30.92 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

05/03/2015

[View](/hr/documents/all-authorised-presentations/xydalba-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (16.38 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

05/03/2015

[View](/is/documents/all-authorised-presentations/xydalba-epar-all-authorised-presentations_is.pdf)

italiano (IT) (16.38 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

05/03/2015

[View](/it/documents/all-authorised-presentations/xydalba-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (34.12 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

05/03/2015

[View](/lv/documents/all-authorised-presentations/xydalba-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (29.39 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

05/03/2015

[View](/lt/documents/all-authorised-presentations/xydalba-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (22.8 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

05/03/2015

[View](/hu/documents/all-authorised-presentations/xydalba-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (32.78 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

05/03/2015

[View](/mt/documents/all-authorised-presentations/xydalba-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (16.52 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

05/03/2015

[View](/nl/documents/all-authorised-presentations/xydalba-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (16.5 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

05/03/2015

[View](/no/documents/all-authorised-presentations/xydalba-epar-all-authorised-presentations_no.pdf)

polski (PL) (32.1 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

05/03/2015

[View](/pl/documents/all-authorised-presentations/xydalba-epar-all-authorised-presentations_pl.pdf)

português (PT) (16.5 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

05/03/2015

[View](/pt/documents/all-authorised-presentations/xydalba-epar-all-authorised-presentations_pt.pdf)

română (RO) (32.34 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

05/03/2015

[View](/ro/documents/all-authorised-presentations/xydalba-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (22.79 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

05/03/2015

[View](/sk/documents/all-authorised-presentations/xydalba-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (22.03 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

05/03/2015

[View](/sl/documents/all-authorised-presentations/xydalba-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (16.04 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

05/03/2015

[View](/fi/documents/all-authorised-presentations/xydalba-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (16.41 KB - PDF)

**First published:**

05/03/2015

**Last updated:**

05/03/2015

[View](/sv/documents/all-authorised-presentations/xydalba-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Xydalba Active substance dalbavancin hydrochloride International non-proprietary name (INN) or common name dalbavancin Therapeutic area (MeSH)

- Soft Tissue Infections
- Skin Diseases, Bacterial

Anatomical therapeutic chemical (ATC) code J01XA04

### Pharmacotherapeutic group

Antibacterials for systemic use

### Therapeutic indication

Xydalba is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and paediatric patients from birth (see sections 4.4 and 5.1). Consideration should be given to official guidance on the appropriate use of antibacterial agents.

## Authorisation details

EMA product number EMEA/H/C/002840 Marketing authorisation holder

AbbVie Deutschland GmbH &amp; Co. KG

Knollstrasse 67061 Ludwigshafen Germany

Opinion adopted 18/12/2014 Marketing authorisation issued 19/02/2015 Revision 22

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Xydalba : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (141.05 KB - PDF)

**First published:** 23/05/2025

**Last updated:** 20/11/2025

[View](/en/documents/procedural-steps-after/xydalba-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Xydalba : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (209.52 KB - PDF)

**First published:** 13/05/2015

**Last updated:** 23/05/2025

[View](/en/documents/procedural-steps-after/xydalba-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Xydalba-H-C-002840-II-0050 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/127606/2025

English (EN) (1.42 MB - PDF)

**First published:** 06/05/2025

[View](/en/documents/variation-report/xydalba-h-c-002840-ii-0050-epar-assessment-report-variation_en.pdf)

Xydalba-H-C-2840-II-0043 : EPAR - Assessment Report

Adopted

Reference Number: EMA/249855/2023

English (EN) (672.02 KB - PDF)

**First published:** 01/08/2023

[View](/en/documents/variation-report/xydalba-h-c-2840-ii-0043-epar-assessment-report_en.pdf)

CHMP post-authorisation summary of positive opinion for Xydalba (II-43)

Adopted

Reference Number: EMA/787460/2022

English (EN) (135.5 KB - PDF)

**First published:** 14/10/2022

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xydalba-ii-43_en.pdf)

Xydalba-H-C-2840-P46-003 : EPAR - Assessment Report

Reference Number: EMA/428555/2020

English (EN) (528.74 KB - PDF)

**First published:** 18/08/2020

[View](/en/documents/variation-report/xydalba-h-c-2840-p46-003-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Xydalba : EPAR - Public assessment report

Adopted

Reference Number: EMA/39820/2015

English (EN) (2.51 MB - PDF)

**First published:** 05/03/2015

**Last updated:** 05/03/2015

[View](/en/documents/assessment-report/xydalba-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Xydalba

Adopted

Reference Number: EMA/CHMP/757915/2014

English (EN) (104.9 KB - PDF)

**First published:** 19/12/2014

**Last updated:** 19/12/2014

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-xydalba_en.pdf)

#### News on Xydalba

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 March 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-march-2025) 28/03/2025

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 October 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-october-2022) 14/10/2022

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 December 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-december-2014) 19/12/2014

#### More information on Xydalba

- [EMEA-000016-PIP01-07-M09 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000016-pip01-07-m09)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 20/11/2025

## Share this page

[Back to top](#main-content)